Iterated cross validation method for prediction of survival in diffuse large B-cell lymphoma for small size dataset

Abstract

Efforts have been made to improve the risk stratification model for patients with diffuse large B-cell lymphoma (DLBCL). This study aimed to evaluate the disease prognosis using machine learning models with iterated cross validation (CV) method. A total of 122 patients with pathologically confirmed DLBCL and receiving rituximab-containing chemotherapy were enrolled. Contributions of clinical, laboratory, and metabolic imaging parameters from fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scans to the prognosis were evaluated using five regression models, namely logistic regression, random forest, support vector classifier (SVC), deep neural network (DNN), and fuzzy neural network models. Binary classification predictions for 3-year progression free survival (PFS) and 3-year overall survival (OS) were conducted. The 10-iterated fivefold CV with shuffling process was conducted to predict the capability of learning machines. The median PFS and OS were 41.0 and 43.6 months, respectively. Two indicators were found to be independent predictors for prognosis: international prognostic index and total metabolic tumor volume (MTVsum) from FDG PET/CT. For PFS, SVC and DNN (both with accuracy 71%) have the best predictive results, of which outperformed other algorithms. For OS, the DNN has the best predictive result (accuracy 76%). Using clinical and metabolic parameters as input variables, the machine learning methods with iterated CV method add the predictive values for PFS and OS evaluation in DLBCL patients.

Differential gene expression analysis pipelines and bioinformatic tools for the identification of specific biomarkers: A review

“…For ROC curves, regularisation can be used to prevent the model from over-fitting the training data, ensuring that the performance, as measured by the area under the curve (AUC), is realistic and reproducible on new datasets [194] . This can be achieved by implementing cross-validation techniques during the training process to evaluate the effectiveness of the model on different subsets of the dataset, ensuring that the model is well-trained and generalizable [195] , [196] . Finally, continuous validation of the model on new data and critical review of the results are essential for maintaining the integrity and robustness of the analyses.…”

Application of Deep Learning in Cancer Prognosis Prediction Model

“…It can be used as a noninvasive method to assist doctors in developing personalized treatment plans. Chang et al 20 systematically compared the performance of DNNs with other machine-learning (logistic regression, random forest, and support vector machine) and DL (fuzzy neural network) models to evaluate 10-year survival in diffuse large B-cell lymphoma. A 10-times fivefold cross-validation approach was used to avoid randomness in the partitioning of the dataset and better reflect the true predictive performance of each model.…”

Segmentation of patients with small cell lung cancer into responders and non-responders using the optimal cross-validation technique

“…Chang et al 2022 [20] evaluated disease prognosis among patients with diffuse large B-cell lymphoma using machine learning models with an iterated CV method [20]. In this study, 5-folds with 10-iterated were conducted, which resulted in 50 testing results.…”